ESMO 2021 | SAKK 08/16: darolutamide maintenance therapy for previously treated patients with mCRPC
Richard Cathomas, MD, PhD, Hospital Graubünden, Chur, Switzerland, discusses the design and the results of the Phase II SAKK 08/16 (NCT02933801) study evaluating darolutamide maintenance therapy in 92 patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone or enzalutamide. Patients were first treated with a taxane and those who achieved disease stabilization were randomized to receive darolutamide or placebo. The primary endpoint of radiographic progression-free survival (rPFS) was met, with a rPFS of 5.5 months for patients in the darolutamide arm versus 4.4 months for patients in the placebo arm. Although there was an improvement in overall survival (OS), it did not reach statistical significance. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Cathomas reports advisory role (institution): MSD, Astra Zeneca, BMS, Roche, Bayer, Astellas, Sanofi, Janssen (personal), Pfizer, Ipsen, Merck, Debiopharm.
Dr Cathomas reports speaker role (institution): Astellas, Janssen (personal).
Dr Cathomas reports travel support (institution): Astra Zeneca.
